GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$0.50
-0.08 (-14.16%)
Open$0.55
Previous Close$0.59
Day High$0.57
Day Low$0.41
52W High$2.68
52W Low$0.50
Volume—
Avg Volume22.4K
Market Cap2.85M
P/E Ratio—
EPS$-3.60
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,317.2% upside
Current
$0.50
$0.50
Target
$17.25
$17.25
$9.83
$17.25 avg
$23.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |
| Rev Growth | +12.1% | -7.4% | -2.7% |
| Debt/Equity | 1.54 | 1.34 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |